<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2512972D-6FE3-48FC-8B6B-CBD2BA6CE18A"><gtr:id>2512972D-6FE3-48FC-8B6B-CBD2BA6CE18A</gtr:id><gtr:name>Missouri University of Science and Tech</gtr:name><gtr:address><gtr:line1>Missouri University of Science and Tech</gtr:line1><gtr:line2>1870 Miner Circle</gtr:line2><gtr:line4>Rolla</gtr:line4><gtr:line5>Missouri</gtr:line5><gtr:postCode>MO 65409</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/66E82ED4-3100-41A5-8513-816860BF2EF8"><gtr:id>66E82ED4-3100-41A5-8513-816860BF2EF8</gtr:id><gtr:firstName>Sarah</gtr:firstName><gtr:otherNames>J</gtr:otherNames><gtr:surname>Payne</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G84%2F6702"><gtr:id>63C9B935-CFBD-462B-8E45-61A8815DE2FC</gtr:id><gtr:title>Regulation of the tumourigenic capacity of breast cancer cells through epithelial-stromal interactions</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G84/6702</gtr:grantReference><gtr:abstractText>Breast carcinoma is one of the most common cancers affecting women in the Western world and, despite advances in detection and treatment, mortality from metastatic disease remains high. Recently it has been demonstrated that not all the tumour cells within a breast cancer are capable of sustaining the growth of that tumour and this means that treatment should be targeted toward the minor subpopulation of cells able to exhibit this capacity. This study is intended to isolate, and then to characterise the properties of, such tumour-sustaining cells. Additionally the impact that a specific component of normal breast tissue, the myoepithelial cell, has on the growth properties of the tumour-sustaining cells will be evaluated since evidence suggests they have tumour-suppressing activity. In high-grade DCIS, a non-invasive form of breast cancer which often progresses to invasive disease, the myoepithelial cells have been shown to express a novel protein at their cell surface. This project will explore the impact that expression of this protein has on the tumour-suppressing capacity of the myoepithelial cells.</gtr:abstractText><gtr:technicalSummary>Breast cancers clearly, from recent experiments, are composed of heterogeneous populations of tumour cells amongst which the cell type capable of sustaining neoplastic growth (the so-called tumour-initiating cell or T-IC) represents a minority population1. Purification of T-IC from breast cancers, using tissue dissaggregation and individual cell sorting according to expression of cell surface markers, has revealed them to possess characteristics similar to those of the stem cell compartment with the retention of limited aspects of normal developmental programmes. Superimposed on this heterogeneity of the neoplastic cells is the heterogeneity of normal, differentiated breast with epithelial lumenal cells, mesenchymal cells and myoepithelial cells all interacting with and influencing cancer development Understanding the nature of the T-ICs and their interaction with the various cellular compartments of the breast is critical for the development of new therapeutic strategies. This study aims to use cell selection and in vivo injection techniques into immuno-compromised mice to evaluate these phenomena using disaggregated human breast cancers. The tumour-inhibiting capacity of normal breast components the myoepithelial cells, and changes to their activity consequent to the expression of a novel integrin heterodimer ( v 6), will be monitored particularly.

Specifically it is intended to confirm the isolation procedures for T-ICs based on the prior work of Al-Hajj and colleagues2; characterise the apparent stem cell nature of such cells using a panel of recently described markers of stem cell phenotype and appropriate functional assays; explore the impact of myoepithelial cells on T-IC capacity using co-injection techniques and monitor the effect that v 6 expression in myoepithelial cells (observed by the host laboratory in over 90% of cases of high-grade ductal carcinoma in situ [DCIS] by immunohistochemistry) has on the tumour-modifying capacity of such cells. This latter aim will be achieved by using retroviral transduction to create stable v 6-expressing myoepithelial lines.</gtr:technicalSummary><gtr:fund><gtr:end>2008-06-05</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-06-06</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>174234</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Cancer Research UK London Research Institute (LRI)</gtr:department><gtr:description>In situ hybridisation analysis for angiogenesis</gtr:description><gtr:id>0169776E-2C74-4B99-889D-DCDAE9C7EC05</gtr:id><gtr:impact>Contributing to manuscript in preparation</gtr:impact><gtr:outcomeId>FB4E44C2721-1</gtr:outcomeId><gtr:partnerContribution>Expertise in the application of in-situ hybridisation to investigate angiogenesis</gtr:partnerContribution><gtr:piContribution>Directed the study and provided tissue samples. Analysis of data.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Fundraisers</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>D12C18CF-2D02-4BBA-A0DA-BA8367C71E9A</gtr:id><gtr:impact>Presented in lay man terms nature of research taking place in the laboratory

Invited to host a study meeting for patient advocate group</gtr:impact><gtr:outcomeId>45C652A4B1F</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Barts and the London School of Medicine and Dentistry Travel Bursary</gtr:description><gtr:end>2009-12-02</gtr:end><gtr:fundingOrg>Queen Mary University of London</gtr:fundingOrg><gtr:id>01E71EC8-55DB-436F-9F2F-5964B32DC032</gtr:id><gtr:outcomeId>nBGfXssBLfM0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>170000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>AICR funding (The role of myoepithelial associated avb6 integrin in modulating angiogenesis in DCIS)</gtr:description><gtr:end>2012-01-02</gtr:end><gtr:fundingOrg>Association for International Cancer Research (AICR)</gtr:fundingOrg><gtr:id>DA87A9D3-758A-452D-830A-B5F9BFAC1B03</gtr:id><gtr:outcomeId>BC250121A900</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Development of new analysis software to quantify tissue and in vitro angiogenic assays</gtr:description><gtr:id>B4276AF7-4239-471B-868B-F58BF0961E14</gtr:id><gtr:impact>More objective quantification of tissue and in vitro angiogenic assays</gtr:impact><gtr:outcomeId>0D4C8A1BF58</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Analytical software</gtr:title><gtr:type>Data analysis technique</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>17EF052A-0F94-4805-9681-CBF126594619</gtr:id><gtr:title>Influence of the tumor microenvironment on angiogenesis.</gtr:title><gtr:parentPublicationTitle>Future oncology (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63fcfe67654528dc5562dee013e84839"><gtr:id>63fcfe67654528dc5562dee013e84839</gtr:id><gtr:otherNames>Payne SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1479-6694</gtr:issn><gtr:outcomeId>aiHieVUUqqC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>333E28F2-F994-4A4B-A060-2E4A2FCD34D9</gtr:id><gtr:title>Predictive markers in breast cancer--the present.</gtr:title><gtr:parentPublicationTitle>Histopathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63fcfe67654528dc5562dee013e84839"><gtr:id>63fcfe67654528dc5562dee013e84839</gtr:id><gtr:otherNames>Payne SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0309-0167</gtr:issn><gtr:outcomeId>01965C63D36</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E1F9862D-D6EA-4609-A28F-0E5C28827653</gtr:id><gtr:title>Altered microenvironment promotes progression of preinvasive breast cancer: myoepithelial expression of av?6 integrin in DCIS identifies high-risk patients and predicts recurrence.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/61de41cef5e0acf82cff59ae4b6ce3a3"><gtr:id>61de41cef5e0acf82cff59ae4b6ce3a3</gtr:id><gtr:otherNames>Allen MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>5469195c5e36d2.44513140</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G84/6702</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>